Department of Ophthalmology, University Hospital of Coimbra, Coimbra, Portugal.
Ophthalmologica. 2012;227(1):39-44. doi: 10.1159/000333213. Epub 2011 Nov 1.
To evaluate the long-term safety and efficacy of intravitreal ranibizumab in the treatment of myopic choroidal neovascularization (CNV).
Three-year retrospective, nonrandomized, interventional case series. Forty eyes of 39 patients with myopic CNV were included; 15 with previous photodynamic therapy, and 25 naïve eyes. Best-corrected visual acuity (BCVA) changes, central foveal thickness (CFT), and number of treatments were assessed, from baseline to month 36.
Mean visual acuity improved from 55.4 Early Treatment Diabetic Retinopathy Study (ETDRS) letters at baseline to 59.7 letters at 12 months (p = 0.07), 61.8 letters at 24 months (p = 0.008) and 63.4 letters at 36 months (p = 0.039). Twenty-five percent of the patients gained ≥15 letters (3 lines) at 12 months, 30% at 24 months and 35% at 36 months. There was a mean reduction of 80 μm in CFT (p < 0.001). A mean of 4.1 injections were performed in the first year, 2.4 in the second year and 1.1 in the third year. Fifty-three percent of the eyes had no need for treatment during the third year of follow-up.
Intravitreal ranibizumab seems to be an effective and safe therapeutic procedure to treat CNV in highly myopic eyes, with a high proportion of patients gaining or stabilizing BCVA at a 3-year follow-up.
评估玻璃体内雷珠单抗治疗高度近视脉络膜新生血管（CNV）的长期安全性和疗效。
回顾性、非随机、干预性病例系列研究，共纳入 39 例患者的 40 只眼，其中 15 只眼有既往光动力疗法史，25 只眼为初治。评估从基线到 36 个月时的最佳矫正视力（BCVA）变化、中心视网膜厚度（CFT）和治疗次数。
平均视力从基线时的 55.4 个早期治疗糖尿病视网膜病变研究（ETDRS）字母提高到 12 个月时的 59.7 个字母（p = 0.07）、24 个月时的 61.8 个字母（p = 0.008）和 36 个月时的 63.4 个字母（p = 0.039）。25%的患者在 12 个月时获得了≥15 个字母（3 行）的提高，30%的患者在 24 个月时，35%的患者在 36 个月时。CFT 平均减少 80μm（p<0.001）。第一年平均注射 4.1 次，第二年 2.4 次，第三年 1.1 次。53%的眼在随访的第 3 年无需治疗。
玻璃体内雷珠单抗似乎是治疗高度近视 CNV 的有效和安全的治疗方法，在 3 年随访中有相当比例的患者提高或稳定了 BCVA。
